Cheng, C.-K.C.-K.ChengTsai, C.-H.C.-H.TsaiShie, J.-J.J.-J.ShieJIM-MIN FANG2018-09-102018-09-102014http://www.scopus.com/inward/record.url?eid=2-s2.0-84903183021&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/386230For the treatment of seasonal flu and possible pandemic infections the development of new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses including the resistant strains is needed. In this review, we summarize previous methods for the structural modification of zanamivir, a potent neuraminidase inhibitor that has rare drug resistance, in order to develop effective anti-influenza drugs. We also report recent research into the design of multivalent zanamivir drugs and bifunctional zanamivir conjugates, some of which have shown better efficacy in animal experiments. As a step towards developing improved antivirals, conjugating anti-influenza drugs with anti-inflammatory agents can improve oral bioavailability and also exert synergistic effect in influenza therapy. ? 2014 Future Science Ltd.[SDGs]SDG3amantadine; anti influenza agent; antiinflammatory agent; antivirus agent; arbidol; influenza vaccine; laninamivir; laninamivir octanoate; oseltamivir; peramivir; protein M2; rimantadine; sialidase inhibitor; unclassified drug; zanamivir; antivirus agent; enzyme inhibitor; sialidase; zanamivir; antiviral resistance; conjugate; drug bioavailability; drug conjugation; drug efficacy; drug potentiation; genome analysis; human; influenza; Influenza virus; life cycle; medical research; nonhuman; photodynamic therapy; priority journal; review; vaccination; analogs and derivatives; animal; antagonists and inhibitors; chemistry; drug design; drug effects; enzymology; Influenza, Human; metabolism; molecularly targeted therapy; Orthomyxoviridae Infections; Orthomyxovirus; physiology; virology; Animals; Antiviral Agents; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Molecular Targeted Therapy; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Zanamivirjournal article10.4155/fmc.14.302-s2.0-84903183021WOS:000337938000010